T0	Participants 224 348	patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.
T1	Participants 370 417	Patients with measurable and assessable disease
T2	Participants 689 754	A total of 474 patients were treated (239 PLD and 235 topotecan).